Objective-Revascularization is an essential process to compensate for cardiac underperfusion and, therefore, preserves cardiac function in the face of chronic ischemic injury. Recent evidence suggested a vital role of aldehyde dehydrogenase 2 (ALDH2) in cardiac protection after ischemia. This study was designed to determine whether ALDH2 regulates chronic ischemia−induced angiogenesis and to explore the underlying mechanism involved. Moreover, the clinical impact of the ALDH2 mutant allele on the development of coronary collateral circulation (CCC) was evaluated. Approach and Results-Mice limb ischemia was performed. Compared with wild-type, ALDH2 deletion significantly reduced perfusion recovery, small artery and capillary density, and increased muscle atrophy in this ischemic model. In vitro, ALDH2-knockdown reduced proliferation, migration and hypoxia triggered endothelial tube formation of endothelial cells, the effects of which were restored by ALDH2 transfection. Further examination revealed that ALDH2 regulated angiogenesis possibly through hypoxia-inducible factor-1α/vascular endothelial growth factor pathways. To further discern the role of ALDH2 deficiency in the function of bone marrow stem/progenitor cells, cross bone marrow transplantation was performed between wild-type and ALDH2-knockout mice. However, there was no significant improvement for wild-type bone marrow transplantation into knockout mice. ALDH2 genotyping was screened in 139 patients with chronic total occlusion recruited to Zhongshan Hospital (2011Hospital ( .10-2014. Patients with poor CCC (Rentrop 0-1; n=51) exhibited a higher frequency of the AA genotype than those with enriched CCC (Rentrop 2-3; n=88; 11.76% versus 1.14%; P=0 0.01). However, the AA group displayed less enriched CCC frequency in Logistic regression model when compared with the GG group (odds ratio=0.08; 95% confidence interval, 0.009-0.701; P=0 0.026). Furthermore, serum vascular endothelial growth factor level tended to be lower in patients with ALDH2 mutation. 
T he reestablishment of blood vessels through the process of angiogenesis, or formation of new blood vessels, is critical to protect the ischemic injury and promote the recovery because of the essential role to deliver oxygen and nutrients. [1] [2] [3] [4] Specifically in cardiovascular system, a functional collateral circulation may counter ischemia to preserve ventricular function and to improve the overall prognosis. [5] [6] [7] [8] Despite the high prevalence of coronary collateral circulation (CCC) in coronary angiogram images from patients with coronary heart disease, particularly chronic total occlusion (CTO), the efficacy of angiogenesis varies from one patient to the next, creating a dramatic inconsistency in the clinical outcome. The underlying mechanisms responsible for such variability seems to be complex and still remains unknown.
Mitochondria aldehyde dehydrogenase (ALDH) or ALDH2 is a key enzyme in eliminating toxic aldehydes by catalyzing their oxidation to nonreactive acids. [13] [14] [15] Accumulating data from our laboratory and others indicated a key protective role for ALDH2 in ischemic injury. [16] [17] [18] These data suggest that ALDH2 is involved in regulation of the microenvironment homeostasis under ischemia or hypoxia condition. Notably, a loss-of-function allele of ALDH2 is found in nearly half of East Asian or 8% of world populations, which may be correlated with various pathological processes, such as ischemia/reperfusion injury and cardiac remodeling. [19] [20] [21] Nonetheless, it remains somewhat elusive whether ALDH2 plays a role in angiogenesis in chronic ischemia.
To this end, this study was designed to investigate the role of ALDH2 in angiogenesis and the underlying molecular basis behind, if any, chronic ischemia. It further prompted us to scrutinize the impact of the Glu504Lys mutation in the development of CCC in the clinical setting. Our results showed that ALDH2 deficiency impairs the angiogenesis process possibly by inhibiting the endothelial cell function and the hypoxiainducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) signaling cascade. On the other side of the coin, overexpression of ALDH2 restores the angiogenesis process. The clinical data implicated that loss-of-function for ALDH2 because of genetic mutation may present as an unfavorable contributing factor for revascularization in patients with CTO. Therefore, targeting on ALDH2 activity might serve as a potential therapeutic strategy for individualized ischemic injury.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

ALDH2 Deficiency Deteriorates Perfusion Recovery and Revascularization in Chronic Hindlimb Ischemia, Leading to Promoted Gastrocnemius Muscle Atrophy
To examine the effect of ALDH2 on perfusion recovery ability in chronic ischemic injury, a mouse ischemic limb model was used in ALDH2-knockout (KO) and wild-type (WT) mice ( Figure 1A ). The perfusion was assayed using the laser Doppler perfusion imaging on days 1, 7, and 21 after the femoral artery ligation surgery ( Figure 1B ). Our results indicated that ALDH2-KO mice displayed reduced perfusion signals (red and orange) associated with more pronounced nonperfusion signals (blue and green) in ischemic limbs compared with those from WT mice on days 7 and 21 (but not on day 1). Quantitatively, we calculated the ratio of perfusion between ischemic and nonischemic limbs for each mouse ( Figure 1C ). Our data revealed that the perfusion ratio achieved 82.2% at the 3-week point in WT group. In comparison, only 59.3% perfusion ratio was found in ALDH2-KO group, whereas there were no significant difference noted between the 2 groups on day 1, indicating a slower recovery of limb circulation (P<0.05; Figure 1B and 1C) . These observations demonstrate that the perfusion recovery of ischemic hindlimb may be impaired by deficient ALDH2 expression.
To determine if deteriorated tissue perfusion was mediated, in part, through reduced revascularization, small artery density was determined 21 days after hindlimb surgery ( Figure 1A and 1D) . Using immunofluorescence staining, small artery was detected by FITC labeled anti-α smooth muscle actin antibody in injured limbs. Less small artery density was found in the injured limbs of ALDH2-KO mice compared with that from the WT mice (22.8±5.2 versus 12.1±5.6 number/field in WT and ALDH2-KO mice, respectively; P<0.05; Figure 1D and 1E). To assess the angiogenesis effect, capillary density was determined at the same time ( Figure 1A and 1F) . Using immunofluorescence stain, capillary density was detected by the anti-CD31 antibody in hindlimbs. The micrographs showed that WT ischemic limb displayed reduced capillary density (less red CD31 (+) signal) compared with WT nonischemic limb. ALDH2-KO ischemic limb displayed the lowest CD31 (+) cell density among the 4 groups. The CD31 (+) cells were significantly less in KO-ischemic group when compared with WT-ischemic group (P<0.05), although the nonischemic limb of ALDH2-KO mice showed equivalent amount of CD31 (+) cells compared with WT mice (0.757±0.036 versus 0.580±0.008 CD31 (+)/ DAPI in (Figure 1E ; P<0.05) WT nonischemic and ischemic limb, and 0.766±0.028 versus 0.402±0.040 (P<0.05) in KO nonischemic and ischemic limb.
Chronic ischemic insult is usually linked to permanent damage to the limb, manifested as muscle atrophy and loss of limb function. 22 Therefore, gastrocnemius muscle atrophy rate was assessed in ischemic limbs, shown as the ratio of weight of ischemic and nonischemic gastrocnemius muscles. Our data revealed somewhat comparable muscle atrophy in ischemic and nonischemic gastrocnemius muscles. Despite the perfusion recovered to >50% of that of the noninjured limb at the 3-week time point. ALDH2-KO mice presented a 25.2% loss of gastrocnemius muscle weight when compared with a 17.5% loss in muscle weight in WT mice (P<0.05; Figure 1F ).
Taken together, these data demonstrate that deficient ALDH2 expression directly impedes the revascularization and perfusion, leading to worsened tissue repair and functional restoration in chronic ischemia.
ALDH2 Deficiency Impairs Tube-Like Construction Formation, Migration, and Proliferation In Vitro
To further determine the regulatory role of ALDH2 in angiogenesis in chronic ischemic microenvironment, the endothelial cell function was evaluated. First, the tube-like construction formation assay was performed in rat cardiac microvascular endothelial cells (; Figure 2A ). To mimic WT and ALDH2-knockdown endothelium, scramble and ALDH2-siRNA were transfected, respectively. Western blot data showed that ALDH2-siRNA downregulated the protein expression of ALDH2 by 70% compared with the control and scramble-siRNA group (Figure 2B and 2C; P<0.05). Indeed, comparable regulation of ALDH2 was noted in microvascular genesis in vitro ( Figure 2D and 2E). There was no significant difference among control, scramble-siRNA, and ALDH2-siRNA groups under normoxia. After a 6-hour hypoxia, formation of capillary-like tubes by microvascular endothelial cells was increased by 2-fold compared with formation of capillary-like tubes by normoxic cells in both control and scramble-siRNA-transfected groups. Interestingly, the hypoxia-induced tube formation of endothelial cells seemed to be negated in ALDH2-siRNA-transfected group (P<0.05; Figure 2D and 2E). The angiogenesis process is also committed to proliferation and migration of endothelial cells. Wound healing assay was performed to evaluate the role of ALDH2 in endothelium migration. To get long-term ALDH2-knockdown and ALHD2-overexpression cell line, and also to reduce mouse euthanization, the following experiment was performed in human umbilical vein endothelial cells. The above row showed the wound at 0 hour, and the below row showed the wound at 6 hour after normoxia or hypoxia ( Figure 2F ). The average migration distance was measured. Quantitatively, (1) compared with normoxia, hypoxia promoted endothelial cell migration in negative control, ALDH2-knockdown, and ALDH2-transfected groups; (2) compared with negative control groups, ALDH2-knockdown suppressed migration both in normoxia (WT, 62.03±2.570 versus ALDH2-knockdown, 32.62±2.695; 1-way ANOVA; P<0.05) and in hypoxia (WT, 87.16±0.4702 versus ALDH2-knockdown, 49.95±5.373; 1-way ANOVA; P<0.05); (3) Conversely, compared with negative control groups, ALDH2 transfection increased migration both in normoxia (62.03±2.570 versus 77.42±2.993; 1-way ANOVA; NS) and in hypoxia (87.16±0.4702 versus 110.7±6.216; 1-way ANOVA; P<0.05; Figure 6G ). Furthermore, CCK-8 assay was used to investigate the regulation of ALDH2 in endothelial proliferation ( Figure 2H ). The result showed the same pattern as in the wound healing assay. Quantitatively, (1) 
ALDH2 Regulates HIF-1α and VEGF Expression In Vitro and In Vivo
To further investigate the molecular mechanisms behind ALDH2-regulated angiogenesis, the HIF-1α/VEGF pathway was evaluated. Control, ALDH2 gain-and loss-function cell models were established using lentiviral vectors to determine the role of ALDH2 in this process. Cells were exposed to normoxia or to hypoxia for 6 hours before assessment of protein levels for HIF-1α and VEGF. The immunoblot analysis depicted a significant increase in the levels of HIF-1α and VEGF in the control group after 6-hour hypoxia, the effect of which was abolished in ALDH2-KO group (P<0.05; Figure 3A and 3C). In contrary, the HIF-1α and VEGF expression showed a significant increase in the ALDH2-transfected group under normoxia. Quantitatively, there is a 2-fold increase in the levels of HIF-1α and VEGF in the ALDH2-transfected group compared with the control normoxic group (equivalent to the control-hypoxia group). After 6-hour hypoxia, the HIF-1α and VEGF expression was increased slightly in ALDH2 overexpression hypoxic group compared with ALDH2 overexpression normoxia group ( Figure 3E , 3G, and 3H). Taken together, these data indicate that ALDH2 is required in HIF-1α/VEGF pathway and that the regulation seemed to be hypoxia independently in vitro.
To investigate whether ALDH2 regulates HIF-1α/VEGF signaling in vivo, expression of these proteins was evaluated in ischemic quadriceps from both nonischemic and ischemic limbs in WT and ALDH2-KO mice, on days 1, 7, and 21 after hindlimb surgery ( Figure 4A ). In this immunoblot analysis, the nonischemia quadriceps of each mouse was used as control. The data revealed that there was no significant increase of the level of HIF-1α/VEGF in WT mice on day 1 after hindlimb ischemia ( Figure 4B , 4D, and 4E). However, ALDH2-KO showed temporary increase of HIF-1α (≈2-fold; P<0.05; Figure 4B and 4D) and VEGF (≈1.5 fold; P<0.05; Figure 4B and 4E). However, interestingly, although there was significant increase of HIF-1α (≈1.2 fold; P<0.05; Figure 4F and 4H) and VEGF (≈1.5 fold; P<0.05; Figure 4F and 4I) in WT mice at the day 7 after surgery, the ALDH2-KO mice showed few accumulation of HIF-1α and VEGF ( Figure 4F , 4H, and 4I). Finally, the expression of HIF-1α and VEGF was comparable between WT and ALDH2-KO groups on day 21 ( Figure 4J, 4L, and 4M ). Several reports have suggested that PHD2, as a cellular oxygen sensor, may regulate HIF-1α protein level through promoting its degradation. Therefore, PHD2 expression was explored in our study ( Figure 4B , 4F, 4G, 4K, 4L, and 4P). However, we did not find any difference in PHD2 protein level among the 4 experimental groups at days 1, 7, and 21, in vivo. These data demonstrated that although ALDH2-KO promoted HIF-1α/VEGF expression transiently early on, it later downregulated the level of HIF-1α/VEGF, which was PHD2 independently, eventually leading to impaired angiogenesis, revascularization, tissue repair, and preservation of function.
ALDH2 Influences the Mobilization But Not the Planting and Repair Effects of Endogenous Stem/Progenitor Cells
Revascularization of ischemic injury is thought to be driven, in part, by the bone marrow stem or progenitor cells. We therefore investigated the effects of ALDH2-KO on endogenous stem/progenitor cells repair and whether such effects contributes to the difference of revascularization between WT and ALDH2-KO mice. First, the mobilization of EPC was measured by flow cytometry at day 7 after hindlimb ischemia, shown as the ratio of CD34 + /Flk1 + cells to mononuclear cells in peripheral blood, and the ratio of CD34 + /Flk1 + cells to bone marrow cells in bone marrow, of both WT and ALDH2-KO mice. Interestingly, circulating EPC of KO mice was significantly increased when compared with WT mice ( Figure 5A ; P<0.05), and the bone marrow EPC was slightly decreased in KO group ( Figure 5B ; NS). We speculated that the enhanced mobilization of EPC in ALDH2-KO mice is a kind of compensatory response to the worse blood supply in ischemic hindlimb. To further test the role of ALDH2 in postischemia endogenous stem/progenitor cells repair, we next performed the cross bone marrow transplantation between WT and ALDH2-KO mice (protocol was shown as Figure 5C ). Assessment of blood perfusion recovery by laser Doppler at day 21 after hindlimb ischemia showed that KO mice with WT bone marrow cells (W2K) displayed worse perfusion than WT mice with WT bone marrow cells (W2W), and KO mice with KO bone marrow cells (K2K) displayed worse perfusion than WT mice with KO bone marrow cells (W2W). There was no difference between WT mice with KO bone marrow and WT mice with WT bone marrow, or between KO mice with KO bone marrow and KO mice with WT bone marrow ( Figure 5D and 5E). Collectively, these data indicated that genotype of recipient was a major determinant affecting the blood perfusion recovery, but not the genotype of bone marrow donor. We also observed the recruitment and planting of bone marrow−derived EPCs to ischemic area by immunofluorescence stain (protocol was shown as Figure 5C ). Before the transplantation, bone marrow stem/progenitor cells purified from WT and ALDH2-KO mice were exposed to GFP-lentiviral for 12 hours, which enabled at least 50% of bone marrow cells to express GFP cont inuously. Therefore, GFP can be used as a marker for bone marrow−derived cells. Immunostaining of tissue from ischemic muscles showed that the there was no significant difference on the number of GFP + /CD31 + cells among the 4 groups, indicating that equivalent level of bone marrow−derived EPC was planted in the ischemic area of these 4 groups, eventually. Taken together, these data demonstrated that although ALDH2-KO mice mobilized more EPC after hindlimb ischemia, the same level of bone marrow−derived EPC was found in the ischemic area, which might be caused by the worse ischemic microenvironments in KO mice. The blood perfusion recovery seemed mostly dependent on the ALDH2 genotype of recipient but not of the bone marrow. Therefore, endogenous stem/ progenitor cell repair was barely the reason of the impaired postischemia revascularization in case of ALDH2 deficiency. 
ALDH2 Glu504Lys Polymorphism Contributes to Poor CCC
The correlation between development of CCC and ALDH2 polymorphism was evaluated in a subset of Chinese patients. As described, collateral circulation by coronary angiography from 139 patients with CTO were examined. The patients were divided into 2 groups, namely poor and enriched CCC (Table 1 ). There were little differences between the 2 groups with regard to sex, age, left anterior descending coronary artery, right coronary artery, type 2 diabetes mellitus, hypertension, smoking, drinking, and hyperlipidemia (Table 1) . Of the 139 patients, 51 (34.09%) patients had poor CCC and 88 (63.31%) displayed enriched CCC. Our result revealed that ALDH2 AA genotype (mutant homozygotes) exhibited a higher frequency in the poor group than in the enriched group ( Table 2; 11.76% versus 1.14%; P=0.01), using a 2-tailed Fisher exact test. Furthermore, the ALDH2 AA homozygotes displayed a significant lower rate in enriched CCC than those carrying at least 1 functional ALDH2*1 allele (WT allele; 14.29% versus 65.91%), resulting in an odds ratio of 0.08 (95% confidence interval, 0.009-0.701; P=0.026) in the logistic regression model. A marginal P value was detected in the association between time duration and CCC, it appeared that longer duration was positively correlated with good CCC (Table 1; 82.35% versus 93.18%; P=0.047). This variant was added into the logistic regression analysis, resulting no significant effect (P>0.05). Therefore, these findings depict that loss-of-function ALDH2 mutation contributes to risk of poor CCC in patients with CTO independently. To recapitulate our laboratory finding in the clinic setting, we further assessed the correlation between the ALDH2 polymorphism and the serum VEGF levels in patients with CTO. Our result revealed that serum VEGF levels displayed a nonsignificant increase in the enriched CCC group compared with those in the poor CCC group (Figure 6A ; 256.4±37.01 versus 233.3±27.79; P=0.618). As expected, patients with ALDH2 mutation displayed a trend of lowered serum VEGF levels compared with patients with WT ALDH2 phenotype ( Figure 6A ; 209.9±20.98 versus 279.5±42.62; P=0.146). These clinical data, therefore, indicated that there may be a correlation between ALDH2 mutation and poor CCC possibly resulted from reduced serum VEGF levels in patients with CTO (Table 3) .
Discussion
The salient findings from this study revealed that global ALDH2 deficiency led to unfavorable vascular sequelae including worsened blood supply after ligation of femoral artery accompanied with fewer numbers of capillary and small arteries, overt muscular atrophy, and reduced capacity of endothelial cells to proliferation, migration, and form tube-like structure. Our data further suggested that the loss of ALDH2-regulated essential angiogenesis factors such as HIF-1α/VEGF pathway may underscore such anomalies. Results from bone marrow transplantation showed that the impaired postischemia repair because of ALDH2 deletion was not related to endogenous stem/progenitor cells. Clinical observation provided compelling evidence in that patients with ALDH2 deficiency were more vulnerable to poor CCC development possibly associated with reduced serum VEGF levels in patients with CTO. Our study demonstrated, for the first time, that ALDH2 possesses an intrinsic capacity to regulate ischemia-/hypoxia-induced angiogenesis, involved in the ischemic microenvironment homeostasis and organ function preservation, via HIF-1α/VEGF cascade, and therefore, the common ALDH2 Glu504Lys mutation exhibit a great clinical impact on the fate of CCC in patients with chronic heart ischemia.
Chronically ischemic tissue, a hallmark for peripheral and coronary artery disease, requires the remodeling from vascular network to reconstitute and sustain its viability. 23, 24 Therefore, therapeutic angiogenesis remains an unmet medical need. However, a tremendous interindividual variability exists in the degree of new collateral formation in patients with coronary artery disease. The observed interindividual heterogeneity may be because of environmental, genetic and epigenetic causes, complications or the severity and duration of disease. [25] [26] [27] Still, the mechanism underneath this interindividual heterogeneity remains poorly understood. Among various potential contributing factors, genetic mutations not only affect the ischemia-angiogenesis response process but also limit the efficiency of revascularization promote therapeutics. To this end, genetic predisposition may be considered as, perhaps, one of the major host factors crucial for the reestablishment of functional collateral circulations. Coronary CTO is considered to be the last frontier of coronary interventional medical specialties. The formation of CCC in patients with CTO is essential to the maintenance of cardiac function. 28, 29 This study showed an inverse correlation between ALDH2 rs671 polymorphism and CCC formation in patients with CTO. Also a nonsignificant correlation was noted between ALDH2 mutation and serum VEGF levels in patients with CTO. However, it is noteworthy that serum rather than plasma samples were used in our study thus may have contaminated the actual plasma values of VEGF because of the interference of platelets and fibrinogen in the serum. These findings should shed some lights toward the interindividual heterogeneity in collateral vessels formation and offer new insights for clinical decision making in the face of ALDH2 mutant individuals.
Our earlier study suggested that mitochondrial isoform of ALDH namely ALDH2 may reduce myocardial infarction injury through regulating the p53/JNK/4-HNE signaling cascade. Furthermore, ALDH2 is capable of mitigating myocardial anomalies through regulating autophagy via a HSP70/JNK/p53-dependent mechanism in doxorubicininduced dilated cardiomyopathy. 30 Our data also revealed that ALDH2 alleviates endoplasmic reticulum stressinduced myocardial anomalies through reduced myocardial apoptosis. [31] [32] [33] [34] These data showed significant protective capacity of ALDH2 through a p53-dependent pathway in cardiomyocytes. However, prolonged or more severe hypoxia has been reported to induce the tumor suppressor p53, which binds to HIF-1α, to promote its degradation and to inhibit its transactivation properties. 35, 36 It was reported that sustained cardiac pressure overload induced an accumulation of p53, resulting in the inhibited HIF-1 activity, impaired cardiac angiogenesis, and ultimately systolic function. 37 This piece of evidence implied that ALDH2 may participate in the angiogenesis progress. Furthermore, our recent study suggested that host ALDH2 regulates transplanted MSC survival and therapy as a microenvironment homeostasis mediator via local capillary density, energy supply, and oxidative stress regulating after ischemia. 38 Therefore, this study provided evidence in support of the hypothesis that ALDH2 may be protective for cardiomyocyte through enhancing homeostasis of microenvironment under ischemic conditions via promoting revascularization and perfusion.
Angiogenesis is the process through which new blood vessels form from pre-existing vessels. This is distinct from vasculogenesis, and is responsible for majority of blood vessel growth during development and in pathological conditions. 39, 40 A hypoxia-inducible program, driven by HIF-1α, renders endothelial cells responsive to angiogenic signals. 41, 42 Normally, when sufficient oxygen is available, HIF-1α may be hydroxylated by the oxygen-sensing enzymes named proteins PHD1-3. And the hydroxylated HIF proteins would next be degraded by proteasomal degradation. Although hypoxia inactive the PHDs, the upregulation of HIF-1 correlates with its combination to the hypoxia response element of its extensive target genes, mainly responsible for oxygen supply and cell survival, such as VEGF, then subsequently initiates the process of angiogenesis. 43, 44 Therefore, the use of HIF-1α inhibitors to block tumor or ocular angiogenesis has received attention, and conversely, HIF-1α gene transfer in mice or activation of HIF-1α promotes ischemic tissue revascularization. In our study, ALDH2 was found to regulate hypoxia-/ ischemia-induced HIF-1α and then accumulation of its downstream angiogenetic protein VEGF. However, this regulation was independent of PHD2. It seems that HIF-1α is not regulated only by the oxygen tension but also by various other stimuli, such as transition metals, nitric oxide, reactive oxygen species, growth factors, and mechanical stresses and the activation of signal proteins, such as p53, Akt, mTOR, MEK1/2, Erk1/2, and so on. 45 Significantly, ALDH2 activity would be strongly affected by genetic mutation. For instance, the common human polymorphism in ALDH2, in which glutamate at amino acid 504 is replaced by lysine, displays a dramatically high prevalence (≈40%) in Asian populations. 46, 47 It is well conceived that ALDH2 acts as a homotetramer or heterotetramer, and all tetramers that contain at least 1 ALDH2*2 subunit being inactive. 48 Therefore, identification of its clinical phenotype is rather important to the health impact of ALDH2 gene. This interindividual heterogeneity may also help to explain the variable angiogenic responses seen in other conditions, such as diabetic retinopathy and solid tumors.
In summary, ALDH2 deficiency compromises regenerative capacity of ischemic tissues as a result of impaired angiogenesis via an HIF-1α-/VEGF-dependent mechanism. Moreover, ALDH2 mutation displayed an inverse correlation coronary collateral vessel formation in patients. This effect is of significant clinical implication as loss-of-function for ALDH2 represents the most popular human genetic mutation. Our findings offer compelling evidence to support that AA genotype may require more aggressive therapeutic attention for vascular recanalization. Last but not least, our investigation revealed therapeutic potential for ALDH2 in the revascularization therapy in patients with coronary heart disease.
Limitation
One obvious limitation noted for the clinical study is that we had little information of the blood supply in patients with CTO before the total occlusion period. Poor blood supply frequently occurs before coronary occlusion and might contribute to the poor CCC. 
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